SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX ... today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock ...

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

Aardvark said it applied to list on the Nasdaq Global Market under the symbol AARD. The company didn't give an expected size for its IPO, nor did it offer an expected price range. Morgan Stanley, B of ...

WARREN, N.J. - PTC Therapeutics (NASDAQ:PTCT) disclosed Thursday that its PTC518 program for Huntington's disease has been granted Fast Track designation by the FDA, a status... PTC Therapeutics ...

today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share. The closing of the offering is expected to occur on or about January 10 ...

Dermata Therapeutics (NASDAQ:DRMA) is raising ~$2.55M in a private offering priced at-the-market under Nasdaq rules. The company is offering 2,007,880 shares of its common stock (or pre-funded ...

Hoth Therapeutics (HOTH ... The company affirms that it has no plans for a public or private offering at this time. Hoth’s financial position remains robust, with a strong balance sheet that ...

--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stoc ...

WARREN, N.J., Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative... SOUTH PLAINFIELD ...